Remdesivir and dexamethasone as tools to relieve hospital care systems stressed by COVID-19: A modelling study on bed resources and budget impactResearch Article Published on 2022-01-122022-10-28 Journal: PLoS ONE [Category] COVID-19, [키워드] affected amplified amplitude Care COVID-19 outbreak COVID-19 patients decrease Dexamethasone drug Effect eligible eligible patient epidemiological data examined France generate High-flow oxygen hospital Hospital stay ICUs Impact intensive care limit low-flow oxygen medications Neutral observé Patient Randomized control trials reductions in Remdesivir required resource second wave significantly Strategy treating Treatment [DOI] 10.1371/journal.pone.0262462 PMC 바로가기 [Article Type] Research Article
Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database입원 COVID-19 환자에서 Remdesivir의 안전 및 임상 결과 : 활발한 감시 데이터베이스의 후 향적 분석Research Article Published on 2022-01-042022-09-10 Journal: BMC Infectious Diseases [Category] SARS, 치료제, [키워드] Active surveillance Administered adverse event Analysis Antibiotics cardiac disease Clinical outcome clinical status Comorbidities concomitant medications conducted COVID-19 Data analysis Data collection database diabete diabetes died Factor High-flow oxygen hospitalised hospitalised patient Hospitalised patients hypertension increased liver enzyme increased liver enzymes India liver enzymes low-flow oxygen management mechanical ventilation men Mortality mortality rate nausea nausea and vomiting non-invasive ventilation oxygen Oxygen therapy Patient patients receiving Remdesivir Result Retrospective analysis Retrospective studies Safety safety profile significantly higher significantly lower steroid Steroids Subgroup analyses subgroup analysis supplementary material treatment for COVID-19 used data vomiting with COVID-19 [DOI] 10.1186/s12879-021-07004-8 PMC 바로가기 [Article Type] Research Article
Clinical features of 375 COVID-19 cases imported from Russia through the Suifenhe port and countermeasuresResearch Article Published on 2021-12-162022-10-28 Journal: PLoS ONE [Category] COVID-19, MERS, [키워드] accounted Admission age Asymptomatic asymptomatic infection baseline body temperature C-reactive protein Chest China clinical Clinical data clinical feature Clinical features Comorbidities Comorbidity cough COVID-19 COVID-19 case COVID-19 patient Critical CRP Disease progression disease severity disease transmission enrolled feature Fever Gender group groups had no High-flow oxygen identify initial symptom lymphocyte majority median age men Mild moderate nasal tube novel coronavirus pneumonia outbreak oxygen Oxygen therapy oxygenation index Patient patients pharyngeal Prevent Result Retrospective study Russia shifting significant difference significantly statistically significant Symptom Symptoms therapeutic therapy undergo WBC White blood cell [DOI] 10.1371/journal.pone.0261437 PMC 바로가기 [Article Type] Research Article
Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients With Severe COVID-19: A Randomized Clinical Trial중증 COVID-19 환자의 침습성 기계 환기 및 임상 회복에 대한 고유량 산소 요법 대 기존 산소 요법의 효과: 무작위 임상 시험Randomized Controlled Trial Published on 2021-12-072022-09-11 Journal: JAMA [Category] SARS, 임상, 치료기술, [키워드] 7-category ordinal scale 95% CI adjusted age Analysis assigned Bacteremia Bacterial bacterial pneumonia calculated clinical clinical recovery clinical trial Comorbidities conducted Conventional COVID-19 Cox proportional hazard Cox proportional hazards model determine distress Effect Endotracheal intubation Follow-up fraction hazard ratio High-flow oxygen high-flow oxygen therapy hospital Hypoxemia Identifier intensive care unit intubation IQR less low-flow oxygen therapy Mechanical mechanical ventilation support median age median time nasal nasal cannula occurred Open-label Ordinal Scale outcome oxygen Oxygen therapy partial pressure partial pressure of arterial oxygen Patient patients randomized Pneumonia proportional hazards model Randomized randomized patients Randomly receive respiratory distress severe COVID-19 severity significantly Suspected Treatment women [DOI] 10.1001/jama.2021.20714 PMC 바로가기 [Article Type] Randomized Controlled Trial
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial입원한 성인 COVID-19(COV-BARRIER) 치료를 위한 바리시티닙의 효능 및 안전성: 무작위, 이중 맹검, 병행군, 위약 대조 3상 시험Clinical Trial Published on 2021-12-012022-09-11 Journal: The Lancet. Respiratory Medicine [Category] Fulltext, SARS, 임상, 치료법, 치료제, [키워드] 1:1 95% CI Abstract addition all-cause mortality anti-inflammatory properties antivirals Asia assigned available data Baricitinib baseline Care Combination company Corticosteroids country death defined Dexamethasone Disease progression dose double-blind Efficacy and safety enrolled Europe evaluate event exploratory Follow-up French frequencies Frequency hazard ratio High-flow oxygen hospitalised inhibitor intention-to-treat population Invasive mechanical ventilation Janus kinase Japanese Lilly material Mortality non-invasive ventilation North America Odds ratio oxygen parallel-group participant Participants Phase 3 phase 3 trial Placebo placebo group placebo-controlled placebo-controlled trial prevented primary endpoint progressed proportion randomised Randomly receive receiving reduced reduction in Registered Remdesivir risk risk difference safety analyses safety analysis safety population safety profile secondary endpoint selective Serious Adverse Event Serious Adverse Events serious infection serious infections South America Spanish Standard Standard of care study drug systemic corticosteroid systemic corticosteroids the placebo group the primary endpoint thromboembolic translation Treatment two groups venous thromboembolic were assessed with COVID-19 [DOI] 10.1016/S2213-2600(21)00331-3 PMC 바로가기 [Article Type] Clinical Trial
Asymptomatic deep vein thromboses in prolonged hospitalized COVID-19 patients장기간 입원한 COVID-19 환자의 무증상 심부정맥 혈전증Article Published on 2021-12-012022-09-11 Journal: Wiener Klinische Wochenschrift [Category] SARS, 치료기술, [키워드] Acquired Acquired coagulation disorders Admission association Asymptomatic body temperature Clinical characteristics clinical suspicion Coagulation coronavirus disease Coronavirus disease 2019 COVID-19 Deep vein Deep vein thrombosis distal Duplex ultrasound DVT event High-flow oxygen hospital discharge Hospitalized hospitalized COVID-19 hospitalized COVID-19 patient ICU IMPROVE incidence intensity intensive care intensive care unit lower extremity majority median other COVID-19 symptoms oxygen Patient patients patients with asymptomatic performed prevalent prevention proximal Pulmonary embolism receiving recognize registry reported SARS-CoV‑2 Screening severe COVID-19 patient severity survivor Survivors systemic inflammation therapeutic doses Thromboprophylaxis thrombosis treat treated venous thromboembolic Venous Thromboembolism Ventilated VTE VTE risk [DOI] 10.1007/s00508-021-01973-1 PMC 바로가기 [Article Type] Article
A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumoniaRandomized Controlled Trial Published on 2021-10-152022-10-04 Journal: The Journal of Clinical Investigation [Category] SARS, 임상, [키워드] 1:1 350 patient 95% CI addition Analysis assigned benefit category clinical trial conducted control arm control group Controlled clinical trial convalescent plasma COVID-19 CP group death ECMO extracorporeal membrane oxygenation greater High-flow oxygen hospital Immunotherapy intention-to-treat Invasive mechanical ventilation multicenter Noninvasive ventilation on mechanical ventilation Open-label Patient patients hospitalized Pneumonia Potential treatment primary endpoint progression proportion Randomized Randomly receiving Spain Standard of care statistical significance statistically survival symptom onset Treatment was performed with COVID-19 [DOI] 10.1172/JCI152740 PMC 바로가기 [Article Type] Randomized Controlled Trial
Remdesivir for the treatment of COVID-19코로나19 치료제 렘데시비르Article Published on 2021-08-052022-09-11 Journal: The Cochrane database of systematic reviews [Category] SARS, 임상, 치료제, [키워드] 95% CI 95% confidence interval adverse event adverse events age all-cause mortality antiviral medicine approach authorisation baseline CENTRAL certainty certainty of evidence chance citation clinical Clinical improvement Clinical outcome clinical outcomes clinical status Cochrane COVID-19 Study Register comparable conducted contribute Controlled controlled trials coronavirus disease coronavirus diseases COVID-19 COVID-19 patient COVID-19 patients COVID-19 research Data collection decrease defined diagnosed died disease severity Effect Efficacy and safety Emergency use Ethnicity evaluated Evidence excluded FIVE Future Gender high risk High-flow oxygen hospitalised hospitalised patient Hospitalised patients identify increase index individual information inhibit initial Invasive mechanical ventilation lack liberation life low-flow oxygen maintain Mask mechanical ventilation media medRxiv methodology Missing data missing value missing values Mortality MOST nasal prong nasal prongs need for oxygen no difference no effect Non-invasive non-invasive mechanical ventilation non-invasive ventilation observation outcome outcomes oxygen participant Participants Patient Placebo potential benefit potential benefits Quality of life randomised randomised controlled trial Randomised controlled trials RCT RCTs receive recruit registry Remdesivir reported required Respiratory Support risk risk difference risk of bia risk ratio RoB 2 SARS-CoV-2 SARS-COV-2 infection Science Citation Index searched Selection Serious Adverse Event Serious Adverse Events severity Source standard care subgroup subgroups supplemental oxygen systematic review Treatment viral replication Web of Science WHO WHO International Clinical Trials Registry Platform worsening [DOI] 10.1002/14651858.CD014962 PMC 바로가기 [Article Type] Article
Differential Cytokine Responses in Hospitalized COVID-19 Patients Limit Efficacy of Remdesivir입원한 COVID-19 환자의 차등 사이토카인 반응은 렘데시비르의 효능을 제한합니다Observational Study Published on 2021-06-282022-09-11 Journal: Frontiers in Immunology [Category] MERS, SARS, 유전자 메커니즘, 임상, 진단, 치료제, [키워드] Analysis BDNF clinical clinical trials COVID-19 COVID-19 patient Critical Critical illness cytokine cytokine IFN-γ Disease progression Effectiveness Efficacy Factor help High-flow oxygen identify IFN-γ IgG subclasse IgG subclasses IgG2 IgG4 IL-4 immune regulation immune response Immunological analyses increase in Invasive mechanical ventilation lack magnitude mechanical ventilation mechanism non-responder observation oxygen Patient PDGF PIGF progression proportion Recovery time reduce Remdesivir remdesivir (GS-5734) Respiratory failure Responder responders response responses severe COVID-19 patients severity of COVID-19 shown significantly higher T-cells therapy tissue repair Treatment Trial upregulation [DOI] 10.3389/fimmu.2021.680188 PMC 바로가기 [Article Type] Observational Study
Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical TrialRandomized Controlled Trial Published on 2021-05-042022-10-05 Journal: JAMA [Category] 임상, [키워드] 28-day mortality 48 hour absolute difference applied assigned clinical COVID-19 Day determine Effect Endotracheal intubation Enrollment Follow-up fraction Free High-flow nasal oxygen High-flow oxygen hospital hypoxemic ICU ICUs in-hospital mortality initial intensive care unit Invasive mechanical ventilation IQR Italy mean difference median median age moderate Mortality nasal oxygen no significant difference Noninvasive ventilation outcome outcomes oxygen participant Patient patients with COVID-19 Positive end-expiratory pressure Primary outcome proportion randomization Randomized randomized clinical trial Randomly receive reported required Research respiratory Respiratory failure Respiratory Support secondary secondary outcome severe hypoxemia significantly higher significantly lower statistically significant study enrollment Support Treatment Trial women [DOI] 10.1001/jama.2021.4682 PMC 바로가기 [Article Type] Randomized Controlled Trial